Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PABPC1 | P11940 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 3/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12582053 | 0.75 | — | — | |
| SCHEMBL27523471 | 0.75 | — | — | |
| SCHEMBL7875758 | 0.75 | — | — | |
| SCHEMBL29392716 | 0.72 | PABPC1 (0.36) | PABPC1CTDSP1GAAHTR1AADRA1D | |
| SCHEMBL9527783 | 0.72 | PABPC1 (0.33) | PABPC1CTDSP1GAAHTR1AADRA1D | |
| SCHEMBL3305308 | 0.71 | PABPC1 (0.44) | PABPC1CTDSP1GAAHTR1AADRA1D | |
| SCHEMBL12944477 | 0.71 | PABPC1 (0.44) | PABPC1CTDSP1GAAHTR1AADRA1D | |
| SCHEMBL12944468 | 0.71 | PABPC1 (0.44) | PABPC1CTDSP1GAAHTR1AADRA1D | |
| SCHEMBL10615776 | 0.70 | PABPC1 (0.43) | PABPC1CTDSP1GAAHTR1AADRA1D | |
| SCHEMBL3308565 | 0.69 | PABPC1 (0.42) | PABPC1CTDSP1GAAHTR1AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041028-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041028-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | CHRM1, CHRM2, CHRM4 | PABPC1 4451/4885CTDSP1 3052/4885GAA 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.